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tiveness of SNM versus OMT and BonT-A.METHODS:AMarkovmodel withMonte-
Carlo simulation was used to assess the ICER of SNM vs. BonT-A and OMT both in
deterministic (base-case) and probabilistic (sensitivity) analysis from a provincial
payer perspective over a 10-year time horizon with 9 month Markov-cycles. Clini-
cal data, healthcare resource utilization and utility scores were acquired from re-
cent publications and an expert panel of 7 surgeons. Cost data (2011 Dollars) were
derived from provincial health insurance policy, drug benefit formulary and hos-
pital data. All cost and outcomeswere discounted at 3% rate. RESULTS: The annual
(year 1-10) incremental QALY for SNM vs. BonT-A was 0.05-0.51 and SNM versus
OMTwas 0.19-1.76. The annual incremental cost of SNM versus BonT-Awas $7,237
in year-1 and -$9,402 in year-10 andwas between $8,878 to -$11,447 vs. OMT. In the
base-case deterministic analysis, the ICER for SNM vs. BonT-A and OMT were
within the acceptable range ($44,837 and $15,130 respectively) at 2nd-year of ther-
apy, and SNM was dominant in consequent years. In the base-case analysis the
probability of ICER being below the acceptability curve of (Willingness-To-
Pay$50,000) was 99% for SNM versus BonT-A at year 3 and 95% for OMT at
year-2. CONCLUSIONS: SNM is a cost-effective treatment option for the manage-
ment of patients with refractory OAB when compared to either BonT-A or OMT.
From a Canadian payers’ perspective, SNM should be considered as first-line treat-
ment option in management of patients with OAB.
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OBJECTIVES: Drug-eluting stents (DES) reduce the need for target repeat revascu-
larization (TVR) compared with bare metal stents (BMS) but are two to three more
expensive. We aim to assess the cost-effectiveness of DES in Hong Kong.
METHODS: Consecutive patients undergoing percutaneous coronary intervention
(PCI) at our institution from September 2009 to September 2010 were evaluated.
Clinical outcomewasmeasured by the occurrence of major adverse cardiac events
(MACE), including death, myocardial infarction and clinically driven TVR. Direct
healthcare costs for index procedure, TVR, and follow-up costs were assessed. An
EQ-5D questionnaire was used to measure quality of life for the baseline and 6
months post PCI. Themain outcomewas the incremental cost-effective ratio (ICER)
for additional cost per TVR avoid and per quality-adjusted life-year (QALY) gained.
Costs are expressed inUS dollars (1USD 7.7HKD).RESULTS:A total of 761 patients
(DES476, BMS285) were evaluated. Clinically driven TVR occurred in 3.6% and
4.2%ofDES andBMSpatients, respectively (p0.68). One year total healthcare costs
was higher for DES patients (US$13,303) than BMS patients (US$12,075, p0.01).
Both groups experienced significant improvement in health utility score at 1 year
compared to baseline but therewas no significant difference betweenDES and BMS
patients (p0.07). QALY gained for DES and BMS patients were 0.415 and 0.375,
respectively (p0.61). The incremental cost per QALY gained was US$30,700 and
per TVR avoided was US$204,667. CONCLUSIONS: In this real-world PCI registry,
the use of DES was associated with significant improvement in quality of life and
low TVR rates which were similar in comparison with BMS. Based on these results,
DES can be considered cost-effective in terms of QALY gained but not for additional
TVR avoided in Hong Kong.
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OBJECTIVES: Early diagnosis of colorectal cancer (CRC) has been shown to improve
life expectancy, and colonoscopy and sigmoidoscopy are cost effective techniques
for CRC diagnosis in older age groups. The objective of this study was to determine
the cost-effectiveness (i.e., cost per QALY) of performing sigmoidoscopy, to check
for neoplasms in the distal colon, before performing colonoscopy in a group of
symptomatic 40-49 year old patients fromaUS societal perspective.METHODS: Los
Angeles County colonoscopy data was reviewed for symptomatic patients without
a family history of CRC to obtain neoplasm rates (N883). Records were collected
from April 2003 to April 2008. Additional parameters for the decision tree analysis
were extracted from a systematic literature review. RESULTS: Diagnostic sigmoid-
oscopy (DS) followed by diagnostic colonoscopy (DC) in patients with a distal ad-
vanced neoplasmwas shown to be themost cost-effective strategy (ICER$48,368),
DS followed by DC in patients with any distal neoplasmwas next (ICER$157,114),
and DC for all symptomatic patients was the least cost-effective (ICER$184,724).
DS followed by DC in patients with any distal neoplasm was sometimes less cost-
effective than DC for all symptomatic patients in a one-way sensitivity analysis. A
threshold analysis was completed for the cost of colonoscopy. CONCLUSIONS: DS
followed by DC in patients with distal advanced neoplasm was shown to be cost-
effective at a $50,000 willingness-to-pay threshold. The other diagnostic strategies
did not meet that threshold. Although, DS followed by DC in patients with any
distal neoplasms nearly met a threshold of $150,000. All strategies were most sen-
sitive to the stage of CRC at diagnosis and the prevalence of patientswith advanced
neoplasm. A colonoscopy cost reduction of over 40%was necessary tomake DC for
all symptomatic patients a cost-effective strategy at a $50,000 threshold and over
25% at a $100,000 threshold.
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OBJECTIVES:To evaluate cost-effectiveness of the implementation, in Colombia, of
different screening strategies for colorectal cancer (CRC): fecal occult blood stool
guaiac test (OB-GT), fecal occult blood immunochemical test (OB-IT), conventional
colonoscopy, sigmoidoscopy, OB-GT followed by sigmoidoscopy, and OB-IT test
plus sigmoidoscopy. METHODS: We designed a Markov model representing the
natural history of CRC in adult Colombians, for the whole lifespan of each individ-
ual, in one-year cycles, using local demographic and epidemiological data. This
model was then modified for each of the screening strategies, assuming detection
rates based on systematic review of the literature. Direct medical costs, from the
Colombian health system perspective (third-party payer), were estimated using
base-case data analysis from the Instituto Nacional de Cancerología (the Colom-
bian national cancer reference center) and applying two different national tariff
manuals (locally known as SOAT and ISS-2001). The costs assigned to each screen-
ing strategy included other diagnostic procedures included in standard protocols
as well as therapy for pre-neoplasic or cancer therapy at different stages of the
disease. A strategy was considered cost-effective if an incremental life year gained
(LYG) costs up to three times the per capita GDP of US$6225. Discount rate was 3%,
for costs and LYG. RESULTS: The cost in US$ per LYG differedmarkedly depending
on the tariff manual used. In both cases, however, biennial OB-GT was cost-effec-
tive (US$10,641 and US$2,694 per LYG), compared with annual OB-GT (US$ 18,902
and US$27,237 per LYG), and biennial OB-IT (US$46.439 and US$14.040 per LYG).
Other screening strategies were clearly not cost-effective under our assumptions.
Probabilistic sensitivity analysis did not change results significantly.
CONCLUSIONS: The most cost-effective screening strategy for CRC in Colombia
(and the only one below our threshold) was biennial feccal occult blood guaiac test.
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OBJECTIVES: Gefitinib, selective epidermal growth factor receptor tyrosine kinase
inhibitor improves progression free survival and overall survival for non-small-cell
lung cancer (NSCLC) patients. However patients with EGFR gene wild-type don’t
benefit from gefitinib. METHODS: We performed cost-effectiveness analysis of
EGFR testing and gefitinib treatment as first-line therapy for NSCLC patients. In our
analysis, we considered three groups:(A) gefitinib treatment for all the patients
without EGFR testing, (B) chemotherapy (carboplatin / paclitaxel) for all the pa-
tients without EGFR testing, and (C) gefitinib treatment for mutation patients and
chemotherapy(carboplatin / paclitaxel) for wild-type patients with EGFR testing.
The cost-effectiveness of two comparison groups was calculated: group A vs. C
(cost-effectiveness of EGFR testing) and and group B versus C (cost-effectiveness of
gefitinib treatment with EGFR testing). Outcome of gefitinib or chemotherapy was
based on Iressa Pan-Asia Study (IPASS) [FukuokaM et al. (2011)]. Onlymedical costs
were included from the perspective of Japanese healthcare payer (the cost of EGFR
testing is JPY 20,000 (USD 260, 1USDJPY77). Discount wasn’t performed because
of short time horizon. RESULTS: ICER of gefitinib with EGFR testing was JPY 900,000
(USD 12,000) (groupA vs. C) per life year gained (LYG) and the ICER of chemotherapy
with EGFR testing was JPY 3,580,000 (USD 46,500) (group B vs. C) per LYG. The cost
of EGFR testing was not influenced on the results. If the cost of EGFR testing is
increased to JPY 80,000 (USD 1,000), the ICER was changed to JPY 1,100,000 (USD
14,000) (group A vs. C) per LYG and JPY 4,870,000 (USD 63,000) per LYG, respectively.
CONCLUSIONS: EGFR testing is cost-effective, however it is not clearly shown that
gefitinb is cost-effective even if EGFR testing is used. EGFR testing is also recom-
mended from the economic perspective if gefitinib is considered to be adminis-
tered.
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OBJECTIVES:Weaim to evaluate the cost-effectiveness of drug-eluting stents (DES)
in a real world setting of multi-vessel percutaneous coronary intervention (PCI).
METHODS: We analyzed 795 consecutive patients undergoing PCI at our institu-
tion. Health outcomeswas estimated in terms of quality adjusted life years (QALYs)
gained measured using EQ-5D at baseline, 6 and 12 months after PCI. Total direct
healthcare costs including cost of index procedure and follow-up costs incurred
over 12 months were calculated. Incremental cost-effective ratio (ICER) per QALY
gained was used to evaluate the cost-utility of DES. RESULTS: Of the 795 patients,
482, 201 and 61 patients underwent single-, 2- and 3-vessel PCI, respectively. DES
was used in 62.7%, 62.6%, 58.7% and 68.9% in overall, single-, 2- and 3-vessel PCI
procedures, respectively. There was progressive increase in QALY gain for patients
who had PCI to 3- (0.43) than in 2- (0.40) and 1-vessel (0.39, p0.01). DES was
associated with higher 1 year total healthcare cost in all 3 groups but was more
effective only in patientswhounderwent 2- and 3-vessel PCIwith an ICER perQALY
gained of US$3,131 and US$21,290, respectively. CONCLUSIONS: In this real-world
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